Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.11
MD's Cash to Debt is ranked higher than
60% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 0.22 vs. MD: 0.11 )
MD' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.11

Equity to Asset 0.74
MD's Equity to Asset is ranked higher than
94% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. MD: 0.74 )
MD' s 10-Year Equity to Asset Range
Min: 0.64   Max: 0.91
Current: 0.74

0.64
0.91
Interest Coverage 83.50
MD's Interest Coverage is ranked higher than
90% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 5.49 vs. MD: 83.50 )
MD' s 10-Year Interest Coverage Range
Min: 6.6   Max: 294.93
Current: 83.5

6.6
294.93
F-Score: 4
Z-Score: 6.28
M-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.99
MD's Operating margin (%) is ranked higher than
94% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. MD: 20.99 )
MD' s 10-Year Operating margin (%) Range
Min: 10.23   Max: 26.38
Current: 20.99

10.23
26.38
Net-margin (%) 13.02
MD's Net-margin (%) is ranked higher than
92% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 4.97 vs. MD: 13.02 )
MD' s 10-Year Net-margin (%) Range
Min: 4.52   Max: 16.21
Current: 13.02

4.52
16.21
ROE (%) 11.97
MD's ROE (%) is ranked higher than
81% of the 229 Companies
in the Global Medical Care industry.

( Industry Median: 8.44 vs. MD: 11.97 )
MD' s 10-Year ROE (%) Range
Min: 4.54   Max: 17.53
Current: 11.97

4.54
17.53
ROA (%) 9.20
MD's ROA (%) is ranked higher than
93% of the 237 Companies
in the Global Medical Care industry.

( Industry Median: 3.63 vs. MD: 9.20 )
MD' s 10-Year ROA (%) Range
Min: 3.38   Max: 12.19
Current: 9.2

3.38
12.19
ROC (Joel Greenblatt) (%) 432.84
MD's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 16.84 vs. MD: 432.84 )
MD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 26.52   Max: 731.54
Current: 432.84

26.52
731.54
Revenue Growth (%) 13.10
MD's Revenue Growth (%) is ranked higher than
89% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. MD: 13.10 )
MD' s 10-Year Revenue Growth (%) Range
Min: 6.9   Max: 45.1
Current: 13.1

6.9
45.1
EBITDA Growth (%) 11.50
MD's EBITDA Growth (%) is ranked higher than
84% of the 171 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. MD: 11.50 )
MD' s 10-Year EBITDA Growth (%) Range
Min: -1.1   Max: 53.8
Current: 11.5

-1.1
53.8
EPS Growth (%) 9.30
MD's EPS Growth (%) is ranked higher than
75% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. MD: 9.30 )
MD' s 10-Year EPS Growth (%) Range
Min: -20.6   Max: 71.7
Current: 9.3

-20.6
71.7
» MD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MD Guru Trades in Q2 2013

Jeremy Grantham 57,700 sh (+12.26%)
Columbia Wanger 687,000 sh (+0.59%)
Jean-Marie Eveillard 4,000 sh (unchged)
Chase Coleman 100,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Mariko Gordon 27,944 sh (-0.14%)
Chuck Royce 1,046,576 sh (-0.82%)
Joel Greenblatt 76,172 sh (-1.36%)
» More
Q3 2013

MD Guru Trades in Q3 2013

Joel Greenblatt 81,977 sh (+7.62%)
Columbia Wanger 687,000 sh (unchged)
Jean-Marie Eveillard 4,000 sh (unchged)
Chase Coleman 100,000 sh (unchged)
Mariko Gordon 27,907 sh (-0.13%)
Jeremy Grantham 53,500 sh (-7.28%)
Chuck Royce 757,007 sh (-27.67%)
» More
Q4 2013

MD Guru Trades in Q4 2013

Vanguard Health Care Fund 805,600 sh (New)
Paul Tudor Jones 9,530 sh (New)
Steven Cohen 20,600 sh (New)
Joel Greenblatt 344,474 sh (+110.1%)
Jean-Marie Eveillard 8,000 sh (unchged)
Mariko Gordon 55,482 sh (-0.59%)
Jeremy Grantham 99,006 sh (-7.47%)
Chuck Royce 1,067,414 sh (-29.5%)
Columbia Wanger 420,000 sh (-69.43%)
» More
Q1 2014

MD Guru Trades in Q1 2014

Jim Simons 5,000 sh (New)
Jeremy Grantham 156,901 sh (+58.48%)
Vanguard Health Care Fund 805,600 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Steven Cohen Sold Out
Columbia Wanger Sold Out
Mariko Gordon 54,010 sh (-2.65%)
Chuck Royce 1,015,114 sh (-4.9%)
Joel Greenblatt 157,284 sh (-54.34%)
Paul Tudor Jones 4,000 sh (-58.03%)
» More
» Details

Insider Trades

Latest Guru Trades with MD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 Reduce -54.34%0.24%$52.85 - $63.2 $ 58.180%157284
Joel Greenblatt 2013-12-31 Add 110.1%0.23%$50.21 - $56.305 $ 58.188%344474
Vanguard Health Care Fund 2013-12-31 New Buy0.13%$50.21 - $56.305 $ 58.188%805600
Joel Greenblatt 2013-03-31 Add 55.76%0.13%$39.76 - $44.82 $ 58.1836%77224
Jean-Marie Eveillard 2012-06-30 Add 33.33%$29.93 - $37.02 $ 58.1876%4000
Joel Greenblatt 2012-03-31 Add 49.08%0.12%$34.04 - $37.73 $ 58.1871%54416
Jean-Marie Eveillard 2012-03-31 New Buy$34.04 - $37.73 $ 58.1871%3000
David Dreman 2011-12-31 Sold Out 0.67%$30.37 - $36.01 $ 58.1875%0
Joel Greenblatt 2011-12-31 Add 27.86%0.07%$30.37 - $36.01 $ 58.1875%36500
Ray Dalio 2011-12-31 Sold Out 0.03%$30.37 - $36.01 $ 58.1875%0
David Dreman 2011-09-30 Reduce -20.47%0.15%$29.31 - $36.83 $ 58.1875%425379
Ray Dalio 2011-09-30 New Buy0.02%$29.31 - $36.83 $ 58.1875%26386
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.40
MD's P/E(ttm) is ranked higher than
88% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 41.50 vs. MD: 20.40 )
MD' s 10-Year P/E(ttm) Range
Min: 6.96   Max: 26.65
Current: 20.4

6.96
26.65
P/B 2.50
MD's P/B is ranked higher than
77% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 2.89 vs. MD: 2.50 )
MD' s 10-Year P/B Range
Min: 0.62   Max: 2.7
Current: 2.5

0.62
2.7
P/S 2.65
MD's P/S is ranked higher than
62% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.63 vs. MD: 2.65 )
MD' s 10-Year P/S Range
Min: 1.12   Max: 3.84
Current: 2.65

1.12
3.84
PFCF 16.40
MD's PFCF is ranked higher than
85% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 33.00 vs. MD: 16.40 )
MD' s 10-Year PFCF Range
Min: 6.33   Max: 20.73
Current: 16.4

6.33
20.73
EV-to-EBIT 12.87
MD's EV-to-EBIT is ranked higher than
89% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 26.76 vs. MD: 12.87 )
MD' s 10-Year EV-to-EBIT Range
Min: 5.3   Max: 16
Current: 12.87

5.3
16
PEG 2.00
MD's PEG is ranked higher than
90% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. MD: 2.00 )
MD' s 10-Year PEG Range
Min: 0.6   Max: 2.15
Current: 2

0.6
2.15
Shiller P/E 24.90
MD's Shiller P/E is ranked higher than
91% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. MD: 24.90 )
MD' s 10-Year Shiller P/E Range
Min: 9.77   Max: 35.64
Current: 24.9

9.77
35.64
Current Ratio 1.78
MD's Current Ratio is ranked higher than
82% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.39 vs. MD: 1.78 )
MD' s 10-Year Current Ratio Range
Min: 0.77   Max: 11.34
Current: 1.78

0.77
11.34
Quick Ratio 1.78
MD's Quick Ratio is ranked higher than
84% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.24 vs. MD: 1.78 )
MD' s 10-Year Quick Ratio Range
Min: 0.77   Max: 11.34
Current: 1.78

0.77
11.34

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.10
MD's Price/DCF (Projected) is ranked higher than
91% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 3.93 vs. MD: 1.10 )
MD' s 10-Year Price/DCF (Projected) Range
Min: 0.46   Max: 277.5
Current: 1.1

0.46
277.5
Price/Median PS Value 1.10
MD's Price/Median PS Value is ranked higher than
81% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. MD: 1.10 )
MD' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 4.03
Current: 1.1

0.2
4.03
Price/Peter Lynch Fair Value 2.00
MD's Price/Peter Lynch Fair Value is ranked higher than
90% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. MD: 2.00 )
MD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.09   Max: 4.44
Current: 2

0.09
4.44
Earnings Yield (Greenblatt) 7.80
MD's Earnings Yield (Greenblatt) is ranked higher than
82% of the 226 Companies
in the Global Medical Care industry.

( Industry Median: 5.20 vs. MD: 7.80 )
MD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.2   Max: 18.8
Current: 7.8

6.2
18.8
Forward Rate of Return (Yacktman) 13.79
MD's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 10.49 vs. MD: 13.79 )
MD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7   Max: 30
Current: 13.79

7
30

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:PDC.Germany
Mednax Inc, was incorporated in Florida in 2007 and is the successor to Pediatrix, which was incorporated in Florida in 1979. The Company is a provider of physician services including Neonatal Care, Maternal-fetal Care, Pediatric Cardiology Care, Other Pediatric Subspecialty Care and Anesthesia Care. At December 31, 2012, its national network comprised 2,100 affiliated physicians, including 1000 physicians who provide neonatal clinical care, in 34 states and Puerto Rico, primarily within hospital-based neonatal intensive care units ("NICUs"), to babies born prematurely or with medical complications. The Company has 200 affiliated physicians who provide maternal-fetal care to expectant mothers experiencing complicated pregnancies and obstetrical hospitalist services in many areas where its affiliated neonatal physicians practice. The Company's network includes other pediatric subspecialists, including 120 physicians providing pediatric cardiology care, 100 physicians providing pediatric intensive care, 60 physicians providing hospital-based pediatric care and 15 physicians providing pediatric surgical care. In addition, It has 625 physicians who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. The Company provides clinical care to babies born prematurely or with complications within specific units at hospitals, mainly NICUs, through a team of experienced neonatal physician subspecialists called 'neonatologists', neonatal nurse practitioners and other pediatric clinicians. The Company provides outpatient and inpatient clinical care to expectant mothers and their unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, such as maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers and genetic counselors. It provides inpatient and outpatient pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease as well as adults with congenital heart defects through its affiliated pediatric cardiologist subspecialists and other clinicians such as pediatric nurse practitioners, echocardiographers and other diagnostic technicians, and exercise physiologists. Its network includes pediatric intensivists, who are hospital-based pediatricians with additional education and training in caring for critically ill or injured children and adolescents, and pediatric hospitalists, who are hospital-based pediatricians specializing in inpatient care and management of acutely ill children. The Company provides anesthesia care through a team of experienced physician anesthesiologists, certified registered nurse anesthetists and anesthesia assistants. It has physicians who provide maternal-fetal medical care to expectant mothers experiencing complicated pregnancies and obstetrician hospitalist services in many areas where its affiliated neonatal
» More Articles for MD

Headlines

Articles On GuruFocus.com
Groups of Gurus Hold 10-Year Low P/B Stocks - ATVI, CHL, MD Dec 20 2013 
5 Inexpensive Stocks for Your Portfolio Jan 19 2012 
Health Care Provider Nov 11 2011 
Mednax, a Quality Healthcare Stock to Consider Oct 18 2011 
MEDNAX, INC. (MD) COO / Pediatrix Division David A. Clark sells 7,456 Shares Dec 10 2010 
MEDNAX, INC. (MD) COO / Pediatrix Division David A. Clark sells 2,960 Shares Dec 03 2010 
MEDNAX, INC. (MD) CFO Vivian Lopez-blanco sells 1,850 Shares Nov 05 2010 
MEDNAX, INC. Reports Operating Results (10-Q) Nov 03 2010 
MEDNAX, INC. Reports Operating Results (10-Q) Aug 03 2010 
MEDNAX, INC. (MD) COO / Pediatrix Division David A. Clark sells 6,755 Shares Jun 03 2010 

More From Our Partners
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan Jul 25 2014 - THESTREET

More From Other Websites
MEDNAX 2014 Second Quarter Conference Call/Webcast Scheduled for Thursday, July 31, 2014 Jul 07 2014
MEDNAX 2014 Second Quarter Conference Call/Webcast Scheduled for Thursday, July 31, 2014 Jul 07 2014
MEDNAX to Present at the William Blair 34th Annual Growth Stock Conference Jun 05 2014
Amsurg up on Sheridan buyout as doctor-service deals draw interest May 29 2014
MEDNAX to Present at the Jefferies 2014 Global Healthcare Conference May 28 2014
Mednax: 3 Different Insiders Have Sold Shares This Month May 12 2014
MEDNAX Announces Data Milestone for Pediatrix Division May 12 2014
Apple sings a different tune with Beats deal May 09 2014
MEDNAX, INC. Financials May 09 2014
MEDNAX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 08 2014
MEDNAX to Present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas May 07 2014
MEDNAX Announces Acquisition of Anesthesiology Practice in New Jersey May 06 2014
MEDNAX, Inc. Earnings Call scheduled for 10:00 am ET today May 01 2014
Mednax, Inc. Discusses Q1 2014 Results (Webcast) May 01 2014
MEDNAX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 01 2014
Q1 2014 MEDNAX, Inc. Earnings Release - Before Market Open May 01 2014
MEDNAX: Q1 included $14M in parity revenue that contributed 4c to EPS May 01 2014
MEDNAX Announces Acquisition of Anesthesiology Practice in New York May 01 2014
MEDNAX Reports 2014 First Quarter EPS of $0.63 May 01 2014
Russia, consumer states discuss gas supply via Ukraine -report Apr 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide